id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-N-3469-0004,FDA,FDA-2015-N-3469,Nomination from Imprimis Pharmaceuticals,Other,Nomination,2015-12-29T05:00:00Z,2015,12,2015-10-27T04:00:00Z,,2017-07-14T20:11:34Z,,0,0,0900006481dd6091
FDA-2015-N-3469-0003,FDA,FDA-2015-N-3469,Request for Nomination from High Chemical Company,Other,Nomination,2015-12-24T05:00:00Z,2015,12,2015-12-24T05:00:00Z,,2015-12-24T14:41:01Z,,0,0,0900006481dcecc3
FDA-2015-N-3469-0001,FDA,FDA-2015-N-3469,"Bulk Drug Substances That Can Be Used To Compound Drug Products in
Accordance With Section 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket",Notice,Notice of Availability,2015-10-27T04:00:00Z,2015,10,2015-10-27T04:00:00Z,2050-02-22T04:59:59Z,2026-01-24T10:08:13Z,2015-27270,1,0,0900006481cf17b1